Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
GlaxoSmithKline ( (GB:GSK) ) has shared an announcement.
GSK announced that the FIRST-ENGOT-OV44 phase III trial for advanced ovarian cancer has met its primary endpoint of progression-free survival. The trial showed that adding Jemperli (dostarlimab) to standard chemotherapy and Zejula (niraparib) maintenance resulted in a statistically significant improvement in progression-free survival compared to the active comparator arm. While the key secondary endpoint of overall survival did not meet statistical significance, further analyses are ongoing. The results of the trial could strengthen GSK’s position in the oncology market, particularly in gynecologic cancers, and provide new hope for patients suffering from advanced ovarian cancer.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company that focuses on uniting science, technology, and talent to tackle diseases. The company is particularly focused on oncology, aiming to maximize patient survival through advances in immuno-oncology and tumor-cell targeting therapies, with a current emphasis on hematologic malignancies, gynecologic cancers, and other solid tumors.
YTD Price Performance: -4.40%
Average Trading Volume: 8,660,150
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £54.43B
For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.
